Key facts
- It has raised $16.2M; the latest was Accelerator/Incubator ($1.0M) in Nov 2025.
- Notable investors include Tech Incubator Program for Startup, KB Investment, Mirae Asset Capital, InterVest, Enlight Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for CTCELLS
- ·The full record, as it builds
Funding rounds
No funding rounds for CTCELLS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CTCELLS
Operator of a cancer diagnostics and drug development platform intended to improve patient outcomes by matching cancer characteristics with the most suitable therapies. The company specializes in drug optimization and membrane-bound protein technology that attaches proteins to natural killer (NK) cell membranes and myelin basic protein (MBP) enhanced Natural Killer (NK) cells to demonstrate prolonged survival and heightened infiltration abilities, enabling patients to reduce the risk of side effects such as immune side effects and maintain the activity of NK cells.
- Sector
- Healthcare
- HQ
- Daegu, South Korea
- Founded
- 2018
- Employees
- 16
- Website
- ctcells.com/
- Ownership
- Privately Held (backing)
CTCELLS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CTCELLS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CTCELLS in its N-PORT filings yet. We sweep new filings monthly.